INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16501, 4201, 'Pioglitazone', 'Diabetes Mellitus, Type 1', 'Thiazolidinediones exert their hypoglycemic effect only in the presence of insulin.  Therefore, these agents should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16502, 6147, 'Pioglitazone', 'Diabetes Mellitus, Type 1', 'Thiazolidinediones exert their hypoglycemic effect only in the presence of insulin.  Therefore, these agents should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16503, 6148, 'Pioglitazone', 'Diabetes Mellitus, Type 1', 'Thiazolidinediones exert their hypoglycemic effect only in the presence of insulin.  Therefore, these agents should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16504, 13442, 'Pioglitazone', 'Diabetes Mellitus, Type 1', 'Thiazolidinediones exert their hypoglycemic effect only in the presence of insulin.  Therefore, these agents should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16505, 13443, 'Pioglitazone', 'Diabetes Mellitus, Type 1', 'Thiazolidinediones exert their hypoglycemic effect only in the presence of insulin.  Therefore, these agents should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16506, 19862, 'Pioglitazone', 'Diabetes Mellitus, Type 1', 'Thiazolidinediones exert their hypoglycemic effect only in the presence of insulin.  Therefore, these agents should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16507, 19952, 'Pioglitazone', 'Diabetes Mellitus, Type 1', 'Thiazolidinediones exert their hypoglycemic effect only in the presence of insulin.  Therefore, these agents should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16508, 19953, 'Pioglitazone', 'Diabetes Mellitus, Type 1', 'Thiazolidinediones exert their hypoglycemic effect only in the presence of insulin.  Therefore, these agents should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16509, 19954, 'Pioglitazone', 'Diabetes Mellitus, Type 1', 'Thiazolidinediones exert their hypoglycemic effect only in the presence of insulin.  Therefore, these agents should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16510, 19956, 'Pioglitazone', 'Diabetes Mellitus, Type 1', 'Thiazolidinediones exert their hypoglycemic effect only in the presence of insulin.  Therefore, these agents should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16511, 24947, 'Pioglitazone', 'Diabetes Mellitus, Type 1', 'Thiazolidinediones exert their hypoglycemic effect only in the presence of insulin.  Therefore, these agents should not be used in patients with type I diabetes or for the treatment of diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16512, 121, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16513, 122, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16514, 3571, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16515, 3572, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16516, 3573, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16517, 3577, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16518, 4200, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16519, 4201, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16520, 6147, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16521, 6148, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16522, 13442, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16523, 13443, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16524, 19862, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16525, 19952, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16526, 19953, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16527, 19954, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16528, 19956, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16529, 24947, 'Pioglitazone', 'Urinary Bladder Neoplasms', 'There are insufficient data to determine if pioglitazone has an effect on preexisting bladder tumors or if it can cause bladder cancer.  However, the manufacturer does not recommend the use of pioglitazone in patients with active bladder cancer.  In patients with history of bladder cancer the benefit of treatment versus the risk of cancer recurrence during treatment should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16530, 121, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16531, 122, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16532, 3571, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16533, 3572, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16534, 3573, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16535, 3577, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16536, 4200, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16537, 4201, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16538, 6147, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16539, 6148, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16540, 13442, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16541, 13443, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16542, 19862, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16543, 19952, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16544, 19953, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16545, 19954, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16546, 19956, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16547, 24947, 'Pioglitazone', 'Edema', 'Thiazolidinediones can cause dose-related edema.  Therapy with thiazolidinediones should be administered cautiously in patients at risk for congestive heart failure as well as those with fluid overload or other conditions that may be adversely affected by excess fluid such as hypertension.  Patients should be monitored for signs and symptoms of heart failure such as dyspnea, swelling of legs or ankles, and weight gain.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16548, 121, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16549, 122, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16550, 3571, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16551, 3572, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16552, 3573, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16553, 3577, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16554, 4200, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16555, 4201, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16556, 6147, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16557, 6148, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16558, 13442, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16559, 13443, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16560, 19862, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16561, 19952, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16562, 19953, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16563, 19954, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16564, 19956, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16565, 24947, 'Pioglitazone', 'Liver Diseases', 'Initiation of rosiglitazone or pioglitazone therapy is not recommended in patients who exhibit clinical evidence of active liver disease or increased baseline serum transaminase levels (ALT exceeding 2.5 times upper limit of normal).  Use of these agents is also not recommended in patients who have experienced jaundice during treatment with troglitazone.  The use of troglitazone, another agent in the thiazolidinedione class, has been associated with clinically significant elevations in liver enzymes, reversible jaundice, and idiosyncratic hepatocellular injury including rare cases of liver failure, liver transplants, and death.  Injury has occurred after both short- and long-term treatment.  While these effects have not been associated with other thiazolidinediones in clinical trials, concerns exist because of their structural similarities.  In addition, isolated cases of hepatitis and hepatic enzyme elevations to 3 or more times the upper limit of normal have been reported with both rosiglitazone and pioglitazone during postmarketing use.  Rarely, these events have involved hepatic failure with and without fatal outcome, although causality has not been established.  Until more safety data are available, patients who are prescribed thiazolidinedione therapy should have serum transaminase levels checked at baseline and periodically thereafter as clinically necessary.  Mild to moderate elevations (ALT less than or equal to 2.5 times ULN) require cautious use with more frequent monitoring to determine if the elevations resolve or worsen.  Patients who develop potential symptoms of hepatic injury such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, and dark urine should have liver enzymes checked.  Therapy should be withdrawn if ALT is elevated and persists above 3 times ULN or if jaundice develops.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16566, 121, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16567, 122, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16568, 3571, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16569, 3572, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16570, 3573, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16571, 3577, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16572, 4200, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16573, 4201, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16574, 6147, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16575, 6148, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16576, 13442, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16577, 13443, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16578, 19862, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16579, 19952, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16580, 19953, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16581, 19954, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16582, 19956, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16583, 24947, 'Pioglitazone', 'Macular Edema', 'New onset or worsening diabetic macular edema with decreased visual acuity have been reported in postmarketing reports in some diabetic patients who were taking thiazolidinedione drugs.  Some patients presented with blurred vision or decreased visual acuity, but some patients appear to have been diagnosed on routine ophthalmologic examination.  Most patients had peripheral edema at the time macular edema was diagnosed.  Some patients had improvement in their macular edema after discontinuation of their thiazolidinedione.  Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care.  Additionally, any diabetic who reports any kind of visual symptom should be promptly referred to an ophthalmologist, regardless of the patient''s underlying medications or other physical findings.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16584, 121, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16585, 122, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16586, 3571, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16587, 3572, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16588, 3573, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16589, 3577, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16590, 4200, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16591, 4201, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16592, 6147, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16593, 6148, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16594, 13442, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16595, 13443, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16596, 19862, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16597, 19952, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16598, 19953, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16599, 19954, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (16600, 19956, 'Pioglitazone', 'Anovulation', 'In premenopausal, anovulatory patients with insulin resistance, treatment with thiazolidinediones may result in resumption of ovulation.  Due to improved insulin sensitivity, pregnancy can occur if adequate contraception is not used.', '2', '', 'DDInter', 0);
